Imaging Endpoints Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Imaging Endpoints's estimated revenue is currently $14M per year.
- Imaging Endpoints's estimated revenue per employee is $159545
- Imaging Endpoints has 88 Employees.
- Imaging Endpoints grew their employee count by 24% last year.
- Imaging Endpoints currently has 14 job openings.
What Is Imaging Endpoints?
Imaging Endpoints (IE) is a mission driven research and imaging CRO with offices in Scottsdale, Arizona and Waltham, Massachusetts. We specialize in providing the industry's leading imaging expertise and most advanced technologies coupled with exquisite services. Our experience extends from translational to phase 3 trials and every step in-between. Our organization is unique in that it is owned by a team of over 40 in-house radiologists and nuclear medicine physicians that specialize in advanced imaging technologies. Our comprehensive services span all aspects of trial planning and conduct, including protocol development, site qualification and standardization, real-time image receipt/QC and reads, data management, regulatory compliance and preparation for meetings/submissions to regulatory authorities. Our Rapid Detection and Assessment of Response program (RaDAR) is designed to accelerate product development by integrating the most advanced imaging technologies into clinical trials. At Imaging Endpoints, our capabilities go above and beyond the typical imaging core lab offering. Learn more at www.imagingendpoints.com.keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Imaging Endpoints News
SCOTTSDALE, Ariz., Sept. 12, 2019 /PRNewswire/ -- Imaging Endpoints (IE) has announced the opening of its new corporate headquarters in ...
The imaging endpoints were mean absolute error (MAE) and mean error (ME), in Hounsfield units (HU), between the reference CT (CTref) and ...
Decision to initiate Phase III program based on effect seen with evobrutinib on magnetic resonance imaging endpoints at 24 weeks and ...
Imaging Endpoints Executive Hires
|2018-08-02||Manual Ramirez||Chief Compliance & Regulatory Affairs Officer||Article|